Year :

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J.—September 15, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please […]

Sep 15, 2022

Legend Biotech Announces Participation in Upcoming Investor Conferences in August

SOMERSET, N.J.—August 19, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Citi’s 17th Annual BioPharma Conference Location: Boston, Massachusetts Fireside Chat Date & Time: Wednesday, September 7, 2022 at 11:20am ET Presenter: […]

Aug 19, 2022

Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

SOMERSET, N.J., December 30, 2021—Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotech’s Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotech’s Board of Directors. Dr. Huang will serve as a Class […]

Dec 30, 2021

Legend Biotech Corporation Announces Pricing of Public Offering

SOMERSET, NJ – December 16, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”),a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public offering of 7,500,000 American depositary shares (“ADSs”), each representing two ordinary shares, at […]

Dec 16, 2021

Legend Biotech Corporation Announces Proposed Public Offering (December 14, 2021)

SOMERSET, NJ – December 14, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it intends to offer and sell $300.0 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, […]

Dec 14, 2021

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.